HOOKIPA Pharma

Inactive

HOOK (PNK)

HOOKIPA Pharma Inc. is a clinical‑stage biopharmaceutical company advancing immunotherapies from its proprietary arenavirus platform. In oncology, HB‑700 targets multiple KRAS mutations; HB‑300 targets prostate cancer. Eseba‑vec is in trials for HPV16+ head and neck cancers (Phase 1/2 enrolled). HB‑400 targets Hepatitis B and HB‑500 targets HIV, both in Phase I. A Gilead collaboration covers HBV and HIV programs. Founded in 2011 and based in New York.